title: Late-phase accumulation of inositol phosphates stimulated by prostaglandins D2 and F2 alpha in neuroblastoma x glioma hybrid NG108-15 cells.
abstract: The accumulation of inositol phosphates (IPs) in response to prostaglandins (PGs) was studied in NG108-15 cells preincubated with myo-[3H]inositol. As a positive control, bradykinin caused accumulation of IPs transiently at an early phase (within 1 min) and continuously during a late phase (15-60 min) of incubation in the cells. PGD2 and PGF2 alpha did not significantly cause the accumulation of IPs at an early phase but significantly stimulated inositol bisphosphate (IP2) and inositol monophosphate (IP) formation at late phase of incubation. The maximum stimulation was obtained at greater than 10(-7) M concentrations of these PGs, the levels being three-and twofold for IP2 and IP1, respectively. 9 alpha, 11 beta-PGF2 has a slight effect but PGE2 and the metabolites of PGD2 and PGF2 alpha have no effect up to 10(-6)M. The effects of PGD2 and PGF2 alpha were not additive, but the effect of each PG was additive to that of bradykinin at a late phase of incubation. Inositol 1-monophosphate was mainly identified in the stimulation by 10(-5) M PGD2 and 10(-5) M PGF2 alpha, whereas both inositol 1-monophosphate and inositol 4-monophosphate were produced in the stimulation by 10(5) M bradykinin. Depletion of extracellular Ca2+ diminished the stimulatory effect of PGD2 and PGF2 alpha and late-phase effect of bradykinin, but simple Ca2+ influx into the cells by high K+, ionomycin, or A23187 failed to cause such late-phase effects. These results suggest that PGD2 and PGF2 alpha specifically stimulate hydrolysis of inositol phospholipids.
authors.affiliation: Hayaishi Bioinformation Transfer Project, Research Development Corporation of Japan, c/o Osaka Medical College.
authors.forename: M
authors.initials: M
authors.lastname: Hatanaka
authors.forename: N
authors.initials: N
authors.lastname: Yumoto
authors.forename: N
authors.initials: N
authors.lastname: Miwa
authors.forename: H
authors.initials: H
authors.lastname: Morii
authors.forename: M
authors.initials: M
authors.lastname: Tanemura
authors.forename: R
authors.initials: R
authors.lastname: Ueno
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: O
authors.initials: O
authors.lastname: Hayaishi
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D015237:Dinoprost / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004533:Egtazic Acid / Q000494:pharmacology; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006822:Hybrid Cells / Q000378:metabolism*; D007295:Inositol Phosphates / Q000378:metabolism*; D007536:Isomerism; D009447:Neuroblastoma / Q000378:metabolism* / Q000473:pathology; D015230:Prostaglandin D2 / Q000494:pharmacology*; D013268:Stimulation, Chemical; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D007295:Inositol Phosphates; D004533:Egtazic Acid; D015237:Dinoprost; D015230:Prostaglandin D2; D001920:Bradykinin; D002118:Calcium